A link between malaria and Burkitt's lymphoma was first described more than 50 years ago, but how a parasitic infection could turn immune cells cancerous has remained a mystery. Now, researchers have demonstrated in mice that B cell DNA becomes vulnerable to cancer-causing mutations.
Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
High rates of freedom from disease, overall survival for standard-dose, with lower-dose EPOCH-R treatment.
A new study that tracked survival during the last decade of more than 2,200 adults with a highly aggressive form of lymphoma has found that medicine has made substantial progress in treating them successfully, with notable exceptions.
The first broad genetic landscape map of a Burkitt lymphoma tumor has identified 70 mutations, including several not previously associated with cancer and a new one that is unique to the disease.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|